Pink Sheet Podcast: Looking Back And Looking Ahead: Key US and EU Legislation
Executive Summary
Pink Sheet reporter and editors discuss key US and EU legislation that impacted 2023 and how it also could affect 2024, including EU legislative reform, US Medicare drug price negotiation, and the US Food and Drug Administration user fee reauthorization.
Pink Sheet Senior Writer Derrick Gingery and executive editors Ian Schofield and Nielsen Hobbs discuss the key legislative initiatives that impacted the pharmaceutical industry and its regulators in 2023 and offer insights on how they may affect 2024, including pending legislative reform in the European Union (:56), as well as implementation of US Medicare drug price negotiation statutes (14:43) and the US Food and Drug Administration’s user fee package (30:57).
More On These Topics From The Pink Sheet
-
European Commission Explains Impact Of EU Pharma Review On SMEs & Non-Profit Entities
-
Biopharma’s Prospects Under A Second Trump Term: They Can’t Get Much Worse
-
These featured topic pages include links to our coverage of EU legislative reform, FDA user fees, and the drug pricing debate
This and all our other podcasts are available on the Pink Sheet podcast page, as well as the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.